# A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

> **NCT06507891** · PHASE1,PHASE2 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** TQ-A3334 tablets
- **DRUG:** TQ-A3334 tablets + Anlotinib capsules

## Key facts

- **NCT ID:** NCT06507891
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-06
- **Primary completion:** 2023-08-25
- **Final completion:** 2024-06-04
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** After considering the company's project situation and strategic development direction, it has been decided to terminate this project. The experiment will be terminated for non safety reasons.
- **Last updated:** 2024-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06507891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06507891, "A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06507891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*